ClinicalTrials.gg
CompletedNCT04482270Updated Oct 17, 2024

A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function

A Phase 1 interventional study of fezolinetant in Hepatic Impairment and Healthy Volunteers, sponsored by Astellas Pharma Global Development, Inc.. Completed at 4 sites in United States. Open to female participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics of a single oral dose of fezolinetant and ES259564 (fezolinetant metabolite) in female participants with mild and moderate hepatic impairment compared to healthy female participants with normal hepatic function.

This study will also evaluate the safety and tolerability of a single oral dose of fezolinetant in female participants with mild and moderate hepatic impairment and healthy female participants with normal hepatic function.

Read the detailed description

The study will comprise of three groups based on hepatic function. Participants will be screened for up to 28 days prior to investigational product (IP) administration on Day 1. Eligible participants will be admitted to the clinical unit on Day -1 and will be residential for a single period of six days/five nights. On Day 1, participants will receive a single oral dose of fezolinetant under fasting conditions followed by a 96-hour in-house blood and urine sampling period. Participants are to remain semirecumbent for four hours postdose. Standard safety and tolerability assessments will be conducted. Participants will be discharged from the clinical unit on Day 5 on the condition that all required assessments have been performed and that there are no medical reasons for a longer stay in the clinical unit.

The study will be completed with an end-of-study visit (ESV). The ESV will take place five to nine days after the last pharmacokinetic sample is collected or at the time of early discontinuation from the study.

02

Conditions studied

  • Hepatic Impairment
  • Healthy Volunteers

Keywords

  • ES259564
  • Pharmacokinetics
  • fezolinetant
  • Healthy Volunteers
  • Hepatic Impairment
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a (BMI) range of 18.5 to 36.0 kg/m\^2, inclusive and weighs at least 50 kg at screening.
  • Female subject is not pregnant and at least one of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who agrees to follow the guidance for at least 30 days prior to day -1 through at least 30 days after IP administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the study period and for 30 days after IP administration.
  • Female subject must not donate ova starting at first dose of IP and throughout the study period and for 30 days after IP administration.
  • Subject agrees not to participate in another interventional study while participating in the present study.

Additional Criterion for Subjects with Hepatic Impairment:

  • Subject has mild ( classification Class A, score 5 or 6) or moderate (Child-Pugh classification Class B, score 7 to 9) hepatic impairment.

Exclusion criteria

Exclusion Criteria:

  • Subject has received any therapy within 28 days or five half-lives, whichever is longer, prior to Day -1.
  • Subject has any condition which makes the subject unsuitable for study participation.
  • Female subject who has been pregnant within six months prior to screening or breastfeeding within three months prior to screening.
  • Subject has a known or suspected to fezolinetant or any components of the formulation used.
  • Subject has had previous exposure with fezolinetant.
  • Subject has used any inducer of cytochrome P450 (CYP) 1A2 in the three months prior or inhibitors of CYP 1A2 in the two weeks or five half-lives of the inhibitor, whichever is longer, prior to Day -1.
  • Subject has any history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies) prior to IP administration.
  • Subject has/had febrile illness or symptomatic, viral (excluding chronic and C), bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within one week prior to Day -1.
  • Subject has smoked, used tobacco-containing products and nicotine or nicotine-containing products (e.g., electronic vapes) within six months prior to screening or the subject tests positive for cotinine at screening or on Day -1.
  • Subject has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within seven days prior to Day -1 and/or received a transfusion of any blood or blood products within 60 days.
  • Subject is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.
  • Subject has creatinine level outside normal limits on Day -1. In such a case, the assessment may be repeated once.

Additional Criteria for Subjects with Hepatic Impairment:

  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, immunologic, metabolic, dermatologic, psychiatric, renal and/or other major disease or , not related to current disease state.
  • Subject has a history of consuming > 7 units of alcoholic beverages per week within three months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within one year prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
  • Subject has a mean pulse \< 45 or > 90 beats per minute (bpm); mean systolic blood pressure (SBP) > 160 millimeters of mercury (mmHg); mean diastolic blood pressure (DBP) > 100 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
  • Subject has a mean interval using Fridericia's formula (QTcF) of > 480 millisecond (msec) on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate (ECG) may be taken.
  • Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1, unless the positive test is due to prescription drug use that is approved by the principal investigator and sponsor.
  • Subject has a positive serology test for hepatitis A virus (HAV) antibodies (immunoglobulin M [IgM]) or antibodies to (HIV) type 1 and/or type 2 at screening.
  • Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period (e.g., advanced ascites, infection of ascites, fever, active gastrointestinal bleeding).
  • Subject who has had a change in dose regimen of medically required medication(s) in the two weeks prior to screening (permitted concomitant medications) and/or subject for whom dose changes are likely to occur during the study (minor dose changes are allowed in agreement with the sponsor) and/or subject has used nonpermitted concomitant medication(s) in the three weeks prior to admission to the clinical unit (nonpermitted concomitant medications include any known hepatic enzyme-altering agents or compounds known to restrict metabolism, vitamins, hormonal , hormone replacement therapy [HRT] and natural and herbal remedies, e.g., St. John's Wort).
  • Subject has a presence of a hepatocellular carcinoma, or an acute liver disease caused by an infection or drug toxicity.
  • Subject has severe portal hypertension or surgical portosystemic shunts, including transjugular intrahepatic portosystemic shunt.
  • Subject has biliary liver cirrhosis, biliary obstruction or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
  • Subject has signs of significant hepatic encephalopathy (hepatic encephalopathy Grade ≥ 2).
  • Subject has severe ascites and/or pleural effusion.
  • Subject has esophageal/gastric variceal bleeding in the past six months prior to screening, unless banded.
  • Subject has level below 40 × 10\^9 per liter and /or \< 90 grams per liter.
  • Subject has previous liver transplantation.

Additional Criteria for Healthy Subjects with Normal Hepatic Function:

  • Subject has any of the liver function tests (alkaline phosphatase [ALP], [ALT], aspartate aminotransferase [AST] and total [TBL]) ≥ 1.5 × the (ULN) or (INR) > 1.1 on Day -1. In such a case, the assessment may be repeated once.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy.
  • Subject has a history of consuming > 7 units of alcoholic beverages per week within six months prior to screening or has a history of alcoholism or drug/chemical/substance abuse within two years prior to screening (note: 1 unit = 12 ounces of beer, 4 ounces of wine, 1 ounce of spirits/hard liquor) or the subject tests positive for alcohol at screening or on Day -1.
  • Subject has any clinically significant abnormality following the physical examination, ECG and protocol-defined clinical laboratory tests at screening or on Day -1.
  • Subject has a mean pulse \< 45 or > 90 bpm; mean SBP > 140 mmHg; mean DBP > 90 mmHg (measurements taken in triplicate after subject has been resting in the supine position for at least five minutes; pulse will be measured automatically) on Day -1. If the mean blood pressure exceeds the limits above, one additional triplicate may be taken.
  • Subject has a mean QTcF of > 450 msec on Day -1. If the mean QTcF exceeds the limits above, one additional triplicate ECG may be taken.
  • Subject has used any prescribed or nonprescribed drugs (including vitamins, hormonal contraceptives, HRT and natural and herbal remedies, e.g., St. John's Wort) in the two weeks prior to IP administration, except for occasional use of acetaminophen (up to 2 g/day) and topical dermatological products, including products.
  • Subject has used any drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and/or opiates) within three months prior to Day -1 or the subject tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates) at screening or on Day -1.
  • Subject has a positive serology test for HAV antibodies (IgM), hepatitis B surface antigen, virus antibodies or antibodies to HIV type 1 and/or type 2 at screening.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Fezolinetant: Mild Hepatic Impairment

    Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

    Drug: fezolinetant

  • Experimental
    Fezolinetant: Moderate Hepatic Impairment

    Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

    Drug: fezolinetant

  • Experimental
    Fezolinetant: Normal Hepatic Function

    Participants will receive a single oral dose of fezolinetant under fasting conditions on Day 1.

    Drug: fezolinetant

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of Fezolinetant in Plasma: Area Under the Concentration-time Curve (AUC) From the Time of Dosing Extrapolated to Time Infinity (AUCinf)

    AUCinf will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  2. PK of Fezolinetant in Plasma: AUC From the Time of Dosing to the Last Measurable Concentration (AUClast)

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  3. PK of Fezolinetant in Plasma: Maximum Concentration (Cmax)

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  4. PK of Fezolinetant in Plasma: Apparent Clearance (CL/F)

    CL/F will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  5. PK of Fezolinetant in Plasma: Apparent volume of Distribution During Terminal Phase After Non-intravenous Administration (Vz/F)

    Vz/F will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  6. PK of Fezolinetant Metabolite ES259564 in Plasma: AUCinf

    AUCinf will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  7. PK of Fezolinetant Metabolite ES259564 in Plasma: AUClast

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

  8. PK of Fezolinetant Metabolite ES259564 in Plasma: Cmax

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 5 days

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    AEs will be coded using Medical Dictionary for Regulatory Activities (MedDRA). An AE is any untoward medical occurrence in a participant administered an IP and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 14 days

  2. Number of Participants With Laboratory Value Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 14 days

  3. Number of Participants With Vital Sign Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 14 days

  4. Number of Participants With 12-lead Electrocardiogram (ECG) Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant 12-lead ECG values.

    Time frame: Up to 14 days

07

Study locations

4 sites
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014-361, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • American Research Corporation
    San Antonio, Texas 72815, United States
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2020
First posted
Jul 22, 2020
StartActual
Sep 2, 2020
Primary completionActual
Mar 22, 2021
CompletionActual
Mar 22, 2021
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04482270
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Sep 2, 2020
Primary completion
Mar 22, 2021
Completion
Mar 22, 2021
Last update
Oct 17, 2024

Study contacts

Executive Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion